Login to Your Account

Genovax Cancer Vaccine Deal a First for Eporgen's Portfolio

By Cormac Sheridan
Staff Writer

Wednesday, December 5, 2012
Eporgen Venture SpA, an Italian early stage venture capital fund with a diversified investor base, has logged the first major transaction of its portfolio, the licensing of a therapeutic cancer vaccine program, GX301, from Genovax srl to Mediolanum Farmaceutici SpA.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription